⌘+K

Pulse Explore Communities Researchers Journals

Home Communities Explore

August 6, 2024Immunotherapy

A red blood cell-based score in the prognostication of patients with metastatic RCC of the Meet-URO 15 study

Shobana Anpalakhan Giuseppe Luigi Banna Sara Elena Rebuzzi Giuseppe Fornarini Marco Maruzzo Paolo Andrea Zucali Fabio Catalano Ludovica Antonj Marianna Tudini Lucia Fratino Andrea Malgeri Pasquale Rescigno Alessio Signori Alessandro Acunzo Enrico Maria Silini Giulia Mazzaschi Sebastiano Buti

View at Publisher

Ask AI

Bookmark

Share

Abstract

Anemia, mean corpuscular volume and red cell distribution width may have some effects on survival outcomes of metastatic renal cell carcinoma (mRCC) patients and are incorporated in a red blood cell (RBC)-based score. Its validity in prognostication of mRCC patients treated with second-line nivolumab was assessed.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Anpalakhan et al. (2024) studied this question.

synapsesocial.com/papers/68e5d467b6db64358756a172 https://doi.org/10.1080/1750743x.2024.2382666

View at Publisher

Ask AI

Bookmark

Share

Keep reading

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1External validation of a red cell-based blood prognostic score in patients with metastatic renal cell carcinoma treated with first-line immunotherapy combinations2024 · 5 citations
2Refining Prognosis in Advanced Renal Cell Carcinoma: International Real-World Validation of the Meet-URO Score in First-Line Immunotherapy CombinationsHuman Clinical Trial · 2026 · 2 citations
3IUC24358-87 Prognostic assessment of the Meet-URO score compared with the IMDC score in metastatic renal cell carcinoma (mRCC) receiving first-line systemic therapies (Meet-URO 33 study)2025
4The prognostic value of Meet-URO score in patients with metastatic clear cell renal cell carcinoma receiving second or third-line tyrosine kinase inhibitors/immune checkpoint inhibitors combination therapy: A real-world study.2024 · 1 citations
5Metastatic Tumour Burden as Prognostic Factor in Nivolumab-Treated Metastatic Renal Cell Carcinoma: An Exploratory StudyOriginal Research · 2026

More related papers

Meet-URO Score Validation in Real-world Patients with Metastatic Renal Cell Carcinoma Receiving First-line Pembrolizumab Plus axitinib: A Subanalysis of the Prospective ProPAXI Study.2025
Evaluating the Prognostic Variables for Overall Survival in Patients with Metastatic Renal Cell Carcinoma: A Meta-Analysis Of 29,366 Patients2024
Real-World Predictors of Response to Immunotherapy in Metastatic Renal Cell Carcinoma: The Emerging Role of the Urologist in Immuno-Oncology2026

More from Immunotherapy

Baseline circulating immunophenotype as a predictor of immune-related adverse events in NSCLC patients treated with immune checkpoint inhibitorsSun,
Circulating and tumor microenvironment immunomarkers associate with immunotherapy efficacy in advanced bladder urothelial carcinoma: an exploratory multicenter study integrating genomic and immunophenotypic profilingFri,